|FOR IMMEDIATE RELEASE|
CELATOR® PHARMACEUTICALS NAMES DR. ARTHUR C. LOUIE AS NEW CHIEF
PRINCETON, NJ, (August 7, 2006) - Celator Pharmaceuticals, a biotechnology company working to develop improved combination chemotherapy, has named Arthur C. Louie, M.D., as chief medical officer. Dr. Louie will direct Celator’s expanding clinical development program targeting new combination therapies to treat a range of cancers.
Dr. Louie is a board certified oncologist with more than 25 years of experience in pharmaceutical research and development. Previously Dr. Louie was a vice president of medical affairs at Human Genome Sciences Inc. and a vice president of clinical research at Xoma Corporation. He also held senior leadership roles in clinical development at Pro-Neuron, Inc. Pro-Virus Inc., and Chiron Therapeutics. He was a director of cancer research at Bristol-Myers Company. Prior to coming to Celator, Dr. Louie consulted for Johnson & Johnson and Genta Incorporated. Among his many professional accomplishments, he was responsible for the successful effort to secure FDA approval for Proleukin IL-2, which is used for treatment of metastatic kidney cancer and for treatment of metastatic melanoma.
“Dr. Louie brings extensive experience in all phases of clinical product research and development to Celator. His outstanding record of success in clinical and regulatory strategy and experience in authoring several FDA submissions within both large and small company settings will be a great asset to our rapidly expanding product development program,” said Andrew Janoff, Ph.D., chairman and CEO of Celator Pharmaceuticals.
# # #